Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03988036
Title A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)
Acronym Keyriched-1
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors West German Study Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU

Facility Status City State Zip Country Details
Universitätsklinikum Tübingen Frauenklinik Tübingen Baden-Württemberg 72076 Germany Details
Breast Center of the University of Munich (LMU) Universitätsfrauenklinik Großhadern Munich Bavaria 80377 Germany Details
Rotkreuzklinikum München GmbH Frauenklinik Munich Bavaria 80637 Germany Details
Niels-Stensen-Kliniken Franziskus-Hospital Harderberg Zentrum für Frauenheilkunde und Abteilung für Senologie Georgsmarienhütte Lower Saxony 49124 Germany Details
Diakoniekrankenhaus Henriettenstiftung GmbH Hannover Lower Saxony 30559 Germany Details
Onkologische Praxis Bielefeld NRW 33604 Germany Details
Onkodok GmbH Gütersloh NRW 33332 Germany Details
St. Elisabeth Krankenhaus GmbH Brustzentrum Köln NRW 50935 Germany Details
Ev. Krankenhaus Bethesda Brustzentrum Niederrhein Mönchengladbach NRW 41061 Germany Details
Praxisnetzwerk Troisdorf NRW 53840 Germany Details
Charité Campus Mitte Klinik für Gynäkologie Berlin 10117 Germany Details
Mammazentrum Hamburg Hamburg 20357 Germany Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field